

## Better planning of your BE studies for Long-acting Antipsychotic Injections

**Long-acting injections (LAIs) of antipsychotic medication (depots)** are being developed specifically to promote treatment adherence and are a valuable option **for maintenance medication in psychotic illnesses.** With a competent team of **300 experienced scientists and a focused approach towards providing quality solutions,** Veeda is well equipped to meet the special clinical trial execution requirements for generic drug development of **Antipsychotic Long-acting Injectables (LAIs).**



### Main challenges for LAI antipsychotics

- 1 **Designing the studies** in line with various regulatory requirements.
- 2 Getting the **stabilized schizophrenic patients** with tolerability assessment.
- 3 Handling of **BENOC requirements** for executing the trial.
- 4 **Patient retention** due to long duration of the trial.

### Few LAI antipsychotics requiring BE studies are

- Aripiprazole depot injection
- Olanzapine modified release injection
- Paliperidone palmitate modified release injection
- Risperidone modified release injection

### Our Capabilities

- Team having experience in understanding the **challenges of study design and logistics of study execution.**
- Consultant Psychiatrist as a key opinion leader, **with over 10 years of clinical trial experience** and having successfully faced 3 US FDA inspections.
- **Investigators database** of more than 40 investigators having prior experience in handling schizophrenic patients.
- Investigators' sites inspected by USFDA.
- Excellent regulatory liaison with proven track record.

### VEEDA CLINICAL RESEARCH PVT. LTD.

Vedant Complex, Beside YMCA club S.G.Highway, Vejalpur,Ahmedabad-380051,Gujarat India



+91 79 3001 3000 |



+91 79 3001 3010 |



info@veedacr.com |



[www.veedacr.com](http://www.veedacr.com)

### Veeda Advantage

Road Map for more than **45 molecules for Patient based Pharmacokinetic Studies** and more than **30 molecules for Clinical End Point Studies**

Proven regulatory track record with **26 USFDA, 5 European, 4 WHO & 5 ANVISA** audits

Two BE studies of LAI antipsychotics are currently in start-up phase

Trusted CRO partner to **10 of the world's top 15 Global Pharmaceutical Companies**

State of the art **Bio-analytical Unit** with more than **550 validated assays** in its library of compounds, **50 NCE methods, 45 complex molecules and 10 more under development.**